| Literature DB >> 30968597 |
Jun Matsubayashi1,2, Shinji Miyake2, Yujin Kudo3, Yoshihisa Shimada3, Junichi Maeda3, Hisashi Saji4, Masatoshi Kakihana3, Jinho Park5, Naohiro Kajiwara3, Shigeru Inoue6, Kazuhiro Saito7, Tatsuo Ohira3, Norihiko Ikeda3, Koichi Tokuuye7, Toshitaka Nagao1,2.
Abstract
BACKGROUND: According to the WHO classification for lung cancer, adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have a better prognosis than invasive adenocarcinoma (IAD). However, detecting the foci of invasion in lung adenocarcinomas radiologically remains difficult. The present study examined whether or not differences in the cytological characteristics between IAD and AIS or MIA (noninvasive or minimally invasive adenocarcinomas [NMIAD]) plays a role in the differential diagnosis.Entities:
Mesh:
Year: 2019 PMID: 30968597 PMCID: PMC6618248 DOI: 10.1002/dc.24171
Source DB: PubMed Journal: Diagn Cytopathol ISSN: 1097-0339 Impact factor: 1.582
Patient characteristics (n = 70)
| Variable | Category | |
|---|---|---|
| Sex | Men | n = 32 (45.7%) |
| Women | n = 38 (54.3%) | |
| Median age (range) | 67 (38‐83) | |
| Median whole tumor size (range) | 1.5 cm (0.6‐3.0 cm) | |
| Histopathological diagnosis | AIS | n = 8 (11.4%) |
| MIA | n = 31 (44.3%) | |
| Lepidic AD | n = 9 (12.9%) | |
| Papillary AD | n = 22 (31.4%) |
Abbreviations: AD, adenocarcinoma; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.
The overall survival
|
|
Abbreviations: 5‐y OS, 5‐year overall survival; AD, adenocarcinoma; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; NS, not significant.
Figure 1A, The overall survival (OS) curve for AIS + MIA (NMIAD) and lepidic and papillary adenocarcinoma (IAD). The 5‐year OS rates were 94.7% and 90.0% for NMIAD and IAD, respectively (P = 0.298). B, The RFS curve for AIS + MIA (NMIAD) and lepidic and papillary adenocarcinoma (IAD). The 5‐year RFS rates were 100% and 82.8% for NMIAD and IAD, respectively (P = 0.003)
The recurrence‐free survival
|
|
Abbreviations: 5‐y RFS, 5‐year recurrence‐free survival; AD, adenocarcinoma; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; NS, not significant.
Figure 2A, The numbers of tumor cells (×10 magnification in 10 fields) were 39.8 ± 28.7 in the AIS + MIA (NMIAD) group and 60.3 ± 40.5 in the IAD group (P = 0.017). B, The numbers of stromal clusters in two slides were 11.8 ± 11.5 in the NMIAD group and 13.3 ± 11.2 in the IAD group (P = 0.591)
Figure 3(A) Large tumor cell clusters (tumor cell clusters composed of ≥20 tumor cells; P = 0.0106), (B) three‐dimensional tumor cell clusters (P = 0.0017), (C) irregular nuclear contours (P = 0.0007), (D) nuclear pleomorphisms (P = 0.2008), (E) prominent nucleoli (P = 0.2484), and (F) intranuclear cytoplasmic inclusion (P = 0.8689)